Bart Barlogie Young Investigator Award for Clinical/Therapeutics
In recognition to the outstanding research developed by Dr. Bart Barlogie in the field of multiple myeloma, the IMS Board of Directors established the Bart Barlogie Young Investigator Award. This award is aimed at formally recognizing and stimulating excellence in myeloma research.
The Young Investigator Award will be given to an investigator under the age of 45 years in recognition of their research in the myeloma field. An award of US $25,000 is given by the IMS at each of the International Myeloma Workshops.
Giampaolo Merlini, MD accepts Bart Barlogie Award on behalf of Giovanni Palladini, MD
Eligible applicants must:
- Be members of IMS in good standing at the time the application is submitted and remain a member of IMS in good standing for the duration of the award funding period. Please see our membership page for more information or contact firstname.lastname@example.org.
- Submit a complete application form to the IMS email@example.com
- Age: Less than 45-years-old by the first date of the Workshop.
The 2019 application period will open January 7, 2019.
- Only electronic email submissions will be accepted.
- Maximum of 3 pages.
- All submissions MUST include the following information:
- Personal data:
- Date of Birth
- Your current position
- Name of the Director of your Research.
- Field of myeloma research interest with a brief description of your clinical/lab/research activities. (one page included in the 3 page submission)
- Research: number of publications specifying original papers, reviews, book chapters, any consensus statements and number of abstract presented at international meetings.
- Funded Research
- Honours and Prizes.
- Teaching and Training activities.
- List your 5 top publications in which you are first or senior author.
- List and briefly explain your 3 top clinical and/or technology achievements/innovations. (one paragraph each)
- Other merits that you would like to mention
Each eligible nomination will be reviewed by the current members of the International Myeloma Society (IMS) Board and members of the Award Subcommittee who hold current membership in the IMS. The members of the IMS Board and the Award Subcommittee will be the electors by voting for only one applicant. Any member, who are directly linked to the applicant will have access to the applications but will not be involved in the voting process.
The awardee will receive $25,000 which can only be used to support the awardee’s myeloma research.
The award will be presented at the next International Myeloma Workshop.
- If selected for an award, the recipient will agree to cite support from the International Myeloma Society (IMS) in any publication resulting from the research conducted during the award period.
- Research award funds cannot be deferred and are non-transferable.
- This award gift does not allow for any indirect costs.
A summary of the research conducted within the two years following the Award must be submitted as a progress report to the IMS Board.
If you have any questions or require additional information regarding the Bart Barlogie Young Investigator Award, please contact firstname.lastname@example.org.
Nomination Call: Monday, January 7, 2019
Nominations are due: Monday, March 25, 2019
Notification of award: Monday, June 17, 2019
Award presentation: At IMW September, 2019
Past Winner Profile
Dr. Palladini has been involved in research in the field of AL amyloidosis since 1994, when he joined the Pavia group led by Dr. Giampaolo Merlini. He earned his MD degree in 1997 and his PhD degree in 2007. He worked as a consultant at the Pavia Amyloidosis Research Center since 2005 and in 2016 he was appointed the Deputy (Head) of the Center. He his Associate Professor of Clinical Chemistry at the University of Pavia.
Dr. Palladini’s research focuses on the diagnosis, prognostic stratification, and treatment of AL amyloidosis. In particular, he explored biomarkers of clonal disease and organ involvement as hints to early diagnosis, prognostic indicators, and markers of response. These studies led to the introduction of N-terminal pro-natriuretic peptide type-B (NT-proBNP) in the management of AL amyloidosis, to the establishment of a staging system for renal involvement, and to the definition of the current criteria for hematologic, cardiac, and renal response in AL amyloidosis.
Dr. Palladini designed and performed or coordinated several clinical trials in AL amyloidosis, introducing oral melphalan and dexamethasone (MDex) as a standard of care for transplant ineligible patients and assessing the safety and efficacy of new drugs in this disease. More recently, he coordinated the first completed international phase III study of novel agents in this disease, comparing MDex with bortezomib plus MDex.